> Details

Rummel, Mathias J.; Al-Batran, Salah E.; Kim, Soo-Z.; Welslau, Manfred; Hecker, Ralf; Kofahl-Krause, Dorothea; Josten, Klaus-M.; Dürk, Heinz; Rost, Andreas; Neise, Michael; von Grünhagen, Ulrich; Chow, Kai U.; Hansmann, Martin-L.; Hoelzer, Dieter; Mitrou, Paris S.

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma
  • Contributor: Rummel, Mathias J.; Al-Batran, Salah E.; Kim, Soo-Z.; Welslau, Manfred; Hecker, Ralf; Kofahl-Krause, Dorothea; Josten, Klaus-M.; Dürk, Heinz; Rost, Andreas; Neise, Michael; von Grünhagen, Ulrich; Chow, Kai U.; Hansmann, Martin-L.; Hoelzer, Dieter; Mitrou, Paris S.
  • imprint: American Society of Clinical Oncology (ASCO), 2005
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.2005.08.100
  • ISSN: 1527-7755; 0732-183X
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Purpose</jats:title><jats:p> The aim of this multicenter-study was to evaluate the progression-free survival, response rate and toxicity of the combination of bendamustine and rituximab (BR) in patients with mantle cell or low-grade lymphomas in first to third relapse or refractory to previous treatment. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> A total of 245 courses (median, four courses per patient) were administered to 63 patients. Bendamustine was given at a dose of 90 mg/m<jats:sup>2</jats:sup> as a 30-minute infusion on days 1 and 2, combined with 375 mg/m<jats:sup>2</jats:sup> rituximab on day 1, for a maximum of four cycles every 4 weeks. Histologies were 24 follicular, 16 mantle cell, 17 lymphoplasmacytoid, and six marginal zone lymphoma. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Fifty-seven of 63 patients responded to BR, corresponding to an overall response rate of 90% (95% CI, 80% to 96%) with a complete remission rate (CR) of 60% (95% CI, 47% to 72%). The median time of progression-free survival was 24 months (range, 5 to 44+ months), and the median duration of overall survival has not yet been reached. In mantle cell lymphomas, BR showed a considerable activity, achieving a response rate of 75% (95% CI, 48% to 93%) with a CR rate of 50%. Myelosuppression was the major toxicity, with 16% grade 3 and 4 leukocytopenia. Thrombocytopenia was rare, with only 3% grade 3 and 4. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> These results demonstrate that the BR combination is a highly active regimen in the treatment of low-grade lymphomas and mantle cell lymphomas. </jats:p></jats:sec>
  • Access State: Open Access